Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dinutuximab Beta→

Dinutuximab Beta Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
C6432H9916N1716O2014S48
Molecular weight
~146800 g/mol
Drug class
Chimeric anti-GD2 monoclonal IgG1 antibodyantineoplastic immunotherapy
Mechanism of action
Binds the GD2 disialoganglioside expressed on neuroblastoma cells and triggers complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to tumour-cell lysis.
Indications / reported uses
  • Treatment of high-risk neuroblastoma in patients aged 12 months and older who previously received induction chemotherapy and achieved at least a partial response, as part of post-consolidation therapy; use with required combination agents and product-specific conditions

Sources: EMA EPAR — Qarziba · EMA product information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dinutuximab Beta Environmental Risk Assessment (ERA) (the Dinutuximab Beta ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.